Trials / Completed
CompletedNCT07073170
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3549492 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-07-25
- Primary completion
- 2026-01-27
- Completion
- 2026-01-27
- First posted
- 2025-07-18
- Last updated
- 2026-03-03
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07073170. Inclusion in this directory is not an endorsement.